• Mashup Score: 0

    October 17, 2023 — The Patel Children’s Heart Institute at St. Joseph’s Children’s Hospital achieved a milestone recently, implanting its 250th congenital transcatheter heart valve.   “This accomplishment reflects the dedication of our entire congenital cardiac team,” said Interventional Cardiologist Dr. Jeremy Ringewald, who is the director of the Cardiac Catheterization Laboratory at St. Joseph’s Children’s Hospital. “Most importantly, this means that we allowed 250 patients in need of pulmonary or tricuspid valve replacement to avoid open-heart surgery.”  Tampa resident John Pino, 57, was the recipient of the 250th valve. He was born with pulmonary stenosis, a heart defect in which the pulmonary valve is narrowed and opens poorly. Pino underwent open-heart surgery when he was 9 years old to open up the narrowed valve, trading blockage for leakage. Eventually, the leakage led to enlargement of his heart and diminished exercise tolerance.  “When it was determined that I would need to

    Tweet Tweets with this article
    • @DAICeditor @StJoesChildren The #PatelChildren's Heart Institute at St. Joseph's Children's Hospital achieved a milestone recently, #implanting its 250th congenital #transcatheter #heartvalve: https://t.co/2hbNrIiV3p

  • Mashup Score: 0

    July 27, 2023 — Abiomed is recalling the Impella Intravascular Left Sided Blood Pumps because the pump’s Instructions for Use (IFU) do not adequately address precautions to take when treating patients who have undergone transcatheter aortic valve replacement (TAVR). The IFU lacks guidance to clinicians on how to manage use of Impella in patients with TAVR and fails to describe how the issue may present if an Impella interacts with TAVR. There is a potential risk that the Impella motor housing may come into contact with the distal stent of a transcatheter aortic valve replacement (TAVR). The contact may damage or destroy the motor’s impeller blades. The damaged Impella system may have reduced blood flow or pump stop, which may delay therapy or fail to provide enough support to the patient. This could be life threatening in people who require high levels of support. There is also a risk that pieces of the broken blades could enter the patient’s bloodstream.  Please be aware, this recall

    Tweet Tweets with this article
    • @DAICeditor #Abiomed is recalling the #Impella Intravascular Left Sided Blood Pumps because the pump’s #IFU do not adequately address precautions to take when treating patients who have undergone #transcatheter #aorticvalve replacement (#TAVR): https://t.co/1SA7FdV5x2

  • Mashup Score: 0

    July 21, 2023 — Onecrea Medical has announced the success of the first-in-human implants of its Transcatheter Aortic Valve Replacement (TAVR) system for the treatment of aortic stenosis. While TAVR technology has been around since 2007, Onecrea Medical’s team of scientists and engineers worked towards creating a next-generation TAVR. A common complication with the TAVR/ procedures is dislodging of the implant or perivalvular leak (PVL) due to an improper fit of the valve. Onecrea Medical’s valve has a unique concave and convex structure that anchors the valve effectively in the aortic annulus. The valve also features differential radial force in different parts, imparting low or high radial forces to the valve depending on the location within the annulus and aorta. In addition, the delivery system has been improved for greater control and accuracy of valve implantation. Crea Aortic valves are rigorously tested for over 200 million fatigue cycles and over 140 days in animal trials. Thes

    Tweet Tweets with this article
    • @DAICeditor #OnecreaMedical has announced the success of the first-in-human implants of its #Transcatheter #Aortic #Valve Replacement (#TAVR) system for the treatment of #aorticstenosis: https://t.co/TZDGUwzz4P

  • Mashup Score: 0

    June 9, 2023 — Dasi Simulations announced it received FDA clearance for its artificial intelligence model for preprocedure transcatheter aortic valve replacement modeling.  The AI (Precision TAVI) is the company’s first product to be cleared by the FDA, according to a company press release.  “Dasi Simulations empowers every heart team with critical insights guaranteeing the identification of the…

    Tweet Tweets with this article
    • @DAICeditor @Dasisimulations #Dasi Simulations announced it received #FDA clearance for its artificial intelligence model for preprocedure #transcatheter #aorticvalve replacement modeling: https://t.co/vIhrEHRDiT

  • Mashup Score: 0

    May 24, 2023 — Medtronic announced two-year results of their Harmony Transcatheter Pulmonary Valve (TPV) System, which treats severe pulmonary regurgitation (PR) in the native or surgically repaired right ventricular outflow tract (RVOT). The analysis demonstrates strong clinical and hemodynamic outcomes for patients with a congenital heart defect of the RVOT and was presented at the Society for…

    Tweet Tweets with this article
    • @DAICeditor @Medtronic Medtronic announced two-year results of their #Harmony #Transcatheter #Pulmonary #Valve (#TPV) System, which treats severe #pulmonary_regurgitation (PR) in the native or surgically repaired right ventricular outflow tract (#RVOT): https://t.co/0nPf0FSaHB

  • Mashup Score: 0

    May 19, 2023 — Abbott announced late-breaking data that add to the body of clinical evidence supporting the benefits of the TriClip transcatheter edge-to-edge repair (TEER) system in treating patients with leaky tricuspid valves. Abbott’s TriClip device is a first-of-its kind, minimally invasive device designed specifically for tricuspid heart valve repair. The results were presented at EuroPCR,…

    Tweet Tweets with this article
    • @DAICeditor @AbbottCardio Abbott announced #latebreaking data that add to the body of #clinical evidence supporting the benefits of the #TriClip #transcatheter edge-to-edge repair (#TEER) system in treating patients with leaky tricuspid valves: https://t.co/aJCjGYHKfn #EuroPCR23

  • Mashup Score: 0

    May 15, 2023 — The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature 15 Late-Breaking Clinical Science studies. An annual meeting featuring cutting-edge research and techniques for structural heart interventions, TVT will take place June 7-10, 2023, at the Phoenix Convention Center – West in Phoenix, Arizona. TVT has become the epicenter of…

    Tweet Tweets with this article
    • @DAICeditor @crf TVT’s #latebreaking #clinical #science will highlight the latest advances in #transcatheter #aorticvalve replacement as well as #mitral, #tricuspid, and #left_atrial_appendage occlusion therapies: https://t.co/B7Y26T1nUo #TVT23